SlideShare uma empresa Scribd logo
1 de 13
Baixar para ler offline
University of Gondar
College of Medicine and Heath Sciences and
University of Gondar comprehensive specialized hospital
Medical Microbiology Laboratory
Annual antibiogram from July 2013 – June 2014 E. C. Specimens are mostly blood and urine.
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Gram positive and Gram negative bacterial isolates (515).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
0
50
100
150
200
250
300
350
400
Penici
llin G
Ampic
illin
Piper
acillin
Oxacil
lin
Piper
acillin
/Tazo
bacta
m
Cefur
oxime
Ceftaz
idime
Ceftri
axone
Cefot
axime
Cefoxi
tin
Mero
pene
m
Amika
cin
Genta
micin
Tobra
mycin
Ciprof
loxaci
n
Trime
thopri
m/Sul
famet
hoxaz
ole
Nitrof
urant
oin
Vanco
mycin
Chlor
amph
enicol
Number 146 46 39 140 161 43 162 255 45 140 259 119 360 61 262 203 58 37 98
%S 9.6 6.5 30.8 42.1 57.8 11.7 23.5 22.7 6.7 42.1 81.9 80.7 47.2 44.3 40.9 31 82.8 59.5 54
Number
&
%
susceptibility
Name of antimicrobial
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Gram negative bacterial isolates (329).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
0
100
200
300
Ampicil
lin
Piperac
illin
Piperac
illin/Taz
obacta
m
Cefurox
ime
Ceftazi
dime
Ceftriax
one
Cefotax
ime
Merop
enem
Amikaci
n
Genta
micin
Tobram
ycin
Ciproflo
xacin
Trimeth
oprim/
Sulfam
ethoxaz
ole
Nitrofu
rantoin
Chlora
mpheni
col
Number 43 37 160 41 157 219 43 256 117 228 58 246 178 56 85
%S 4.7 32.4 57.5 9.8 24.2 20.1 4.7 82 81.2 43.4 41.4 39 25.8 82.1 52.9
Number
&
%
susceptibility
Name of antimicrobial
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH NICU for all Gram negative bacterial isolates (132).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
 NICU = Neonatal intensive care unit
0
20
40
60
80
100
120
Piperacillin
/Tazobacta
m
Ceftazidim
e
Ceftriaxone Meropene
m
Amikacin Gentamicin Ciprofloxaci
n
Trimethopr
im/Sulfame
thoxazole
Chloramph
enicol
Number 71 60 85 103 41 97 99 71 38
%S 64.8 25 24.7 83.5 75.6 36 45.5 35.2 39.5
Number
&
%
Susceptibility
Name of antimicrobial
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH NICU for all E. coli bacterial isolates (89).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
 NICU = Neonatal intensive care unit
0
10
20
30
40
50
60
70
80
90
100
Piperacillin/
Tazobacta
m
Ceftazidime Ceftriaxone Meropene
m
Amikacin Gentamicin Ciprofloxaci
n
Trimethopri
m/Sulfamet
hoxazole
Nitrofurant
oin
Number 39 41 62 75 34 65 64 50 35
%S 61.5 22 22.6 97.3 85.3 60 25 20 85.7
Number
&
%
susceptibility
Name of antimicrobial
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all K. pneumoniae isolates (127).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
0
20
40
60
80
100
120
Piperacillin/
Tazobactam
Ceftazidime Ceftriaxone Meropene
m
Amikacin Gentamicin Ciprofloxaci
n
Trimethopri
m/Sulfamet
hoxazole
Chloramph
enicol
Number 62 57 83 101 38 84 88 72 40
%S 51.6 22.8 14.5 78.2 84.2 23.8 38.6 26.4 50
Number
&
%
susceptibility
Name of antimicrobial
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Klebsella spps isolates (144).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
0
20
40
60
80
100
120
Piperacilli
n/Tazobac
tam
Ceftazidim
e
Ceftriaxon
e
Meropene
m
Amikacin Gentamici
n
Tobramyci
n
Ciprofloxa
cin
Trimethop
rim/Sulfa
methoxaz
ole
Chloramp
henicol
Number 69 66 95 115 46 96 30 101 82 48
%S 50.7 24.2 14.7 79.1 82.6 27.1 36.7 38.6 25.6 52.1
Number
&
%
susceptibility
name of antimicrobial
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH NICU for all Klebsella spps isolates (86).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
 NICU = Neonatal intensive care unit
0
10
20
30
40
50
60
70
80
90
Piperacillin/T
azobactam
Ceftazidime Ceftriaxone Meropenem Gentamicin Ciprofloxacin Trimethopri
m/Sulfameth
oxazole
Chloramphen
icol
Number 45 32 50 70 59 56 47 32
%S 60 15.6 14 82.9 20.3 37.5 29.8 40.6
Number
&
%
susceptibility
Name of antimicrobia
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Non fermenter bacterial isolates including Acinetobacter spps
and Pseudomonas spps (67).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
0
10
20
30
40
50
60
70
Piperacillin/Tazob
actam
Ceftazidime Ceftriaxone Meropenem Gentamicin Ciprofloxacin
Number 40 32 42 49 49 57
%S 57.5 31.3 26.2 65.3 53.1 56.1
Number
&
%
susceptibility
Name of antimicrobial
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Gram positive bacterial isolates (180).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
0
20
40
60
80
100
120
140
160
Penicillin G Oxacillin Ceftriaxone Cefoxitin Gentamicin Vancomycin
Number 146 140 30 140 127 37
%S 9.6 42.1 43.3 42.1 54.3 59.5
Number
&
%
susceptibility
Name of antimicrobial
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all S. aureus isolates (141).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
0
20
40
60
80
100
120
140
Penicillin G Oxacillin Cefoxitin Gentamicin
Number 132 137 137 125
%S 6.1 43.1 43.1 54.4
Number
&
%
susceptibility
Name of antimicrobial
Number %S
Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH NICU ward for all S. aureus isolates (55).
Key:
 Number = Number of each antimicrobial repeatedly tested
 %S = %susceptibility
 NICU = Neonatal intensive care unit
0
10
20
30
40
50
60
Penicillin G Oxacillin Cefoxitin Gentamicin
Number 55 54 54 53
%S 3.6 40.7 40.7 43.4
Number
&
%
susceptibility
Name of antimicrobial
Number %S
2014 E. C UoGCSHL Antibiogram pdf.pdf

Mais conteúdo relacionado

Semelhante a 2014 E. C UoGCSHL Antibiogram pdf.pdf

COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETE...
COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETE...COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETE...
COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETE...EuFMD
 
20180524 antibiotic resistance and the risk of recurrent bacteremia
20180524 antibiotic resistance and the risk of recurrent bacteremia20180524 antibiotic resistance and the risk of recurrent bacteremia
20180524 antibiotic resistance and the risk of recurrent bacteremiaNational Yang-Ming University
 
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...EuFMD
 
DIAGNOSTIC PERFORMANCE OF FOOT-AND-MOUTH DISEASE VIRUS DETECTION AND SEROTYPI...
DIAGNOSTIC PERFORMANCE OF FOOT-AND-MOUTH DISEASE VIRUS DETECTION AND SEROTYPI...DIAGNOSTIC PERFORMANCE OF FOOT-AND-MOUTH DISEASE VIRUS DETECTION AND SEROTYPI...
DIAGNOSTIC PERFORMANCE OF FOOT-AND-MOUTH DISEASE VIRUS DETECTION AND SEROTYPI...EuFMD
 
Prevalence of Vancomyc in-resistant Enterococci SSGH (A study of total 300 is...
Prevalence of Vancomyc in-resistant Enterococci SSGH (A study of total 300 is...Prevalence of Vancomyc in-resistant Enterococci SSGH (A study of total 300 is...
Prevalence of Vancomyc in-resistant Enterococci SSGH (A study of total 300 is...iosrjce
 
Informe sobre la situación del uso de antimicrobianos en España
Informe sobre la situación del uso de antimicrobianos en EspañaInforme sobre la situación del uso de antimicrobianos en España
Informe sobre la situación del uso de antimicrobianos en EspañaSEMPSPH
 
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for PigsDr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for PigsJohn Blue
 
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for PigsDr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for PigsJohn Blue
 
WYETH 2009 ICAAC POSTER 1
WYETH 2009 ICAAC POSTER 1WYETH 2009 ICAAC POSTER 1
WYETH 2009 ICAAC POSTER 1Venkat Alluru
 
9 stephen mulligan
9 stephen mulligan9 stephen mulligan
9 stephen mulliganspa718
 
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療Ks doctor
 
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...EuFMD
 
5-Clinical_evaluation_data-_SARS-CoV-2_-Lin_Chuang_Bao_Gao_.pdf
5-Clinical_evaluation_data-_SARS-CoV-2_-Lin_Chuang_Bao_Gao_.pdf5-Clinical_evaluation_data-_SARS-CoV-2_-Lin_Chuang_Bao_Gao_.pdf
5-Clinical_evaluation_data-_SARS-CoV-2_-Lin_Chuang_Bao_Gao_.pdfMonicaLemos11
 
study of egfr protein expression by Immunohistochemistry and mutation check b...
study of egfr protein expression by Immunohistochemistry and mutation check b...study of egfr protein expression by Immunohistochemistry and mutation check b...
study of egfr protein expression by Immunohistochemistry and mutation check b...premvarma064
 
Study on Sensitivity Pattern of Micro-Organisms in Respiratory Tract Infectio...
Study on Sensitivity Pattern of Micro-Organisms in Respiratory Tract Infectio...Study on Sensitivity Pattern of Micro-Organisms in Respiratory Tract Infectio...
Study on Sensitivity Pattern of Micro-Organisms in Respiratory Tract Infectio...iosrjce
 
J World's Poult Res 5(2) 21-28, 2015
J World's Poult Res 5(2) 21-28, 2015J World's Poult Res 5(2) 21-28, 2015
J World's Poult Res 5(2) 21-28, 2015Hany Ellakany
 

Semelhante a 2014 E. C UoGCSHL Antibiogram pdf.pdf (20)

COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETE...
COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETE...COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETE...
COMPARISON OF DIAGNOSTIC PERFORMANCES OF THREE COMMERCIAL ELISA KITS FOR DETE...
 
20180524 antibiotic resistance and the risk of recurrent bacteremia
20180524 antibiotic resistance and the risk of recurrent bacteremia20180524 antibiotic resistance and the risk of recurrent bacteremia
20180524 antibiotic resistance and the risk of recurrent bacteremia
 
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
DEVELOPMENT OF SOLID-PHASE COMPETITION ELISA FOR DETECTION OF TYPE-A FOOT AND...
 
DIAGNOSTIC PERFORMANCE OF FOOT-AND-MOUTH DISEASE VIRUS DETECTION AND SEROTYPI...
DIAGNOSTIC PERFORMANCE OF FOOT-AND-MOUTH DISEASE VIRUS DETECTION AND SEROTYPI...DIAGNOSTIC PERFORMANCE OF FOOT-AND-MOUTH DISEASE VIRUS DETECTION AND SEROTYPI...
DIAGNOSTIC PERFORMANCE OF FOOT-AND-MOUTH DISEASE VIRUS DETECTION AND SEROTYPI...
 
anti tumor 1.doc
anti tumor 1.docanti tumor 1.doc
anti tumor 1.doc
 
Prevalence of Vancomyc in-resistant Enterococci SSGH (A study of total 300 is...
Prevalence of Vancomyc in-resistant Enterococci SSGH (A study of total 300 is...Prevalence of Vancomyc in-resistant Enterococci SSGH (A study of total 300 is...
Prevalence of Vancomyc in-resistant Enterococci SSGH (A study of total 300 is...
 
ICN Victoria: Cornely on "Being a Fun-gi in ICU"
ICN Victoria: Cornely on "Being a Fun-gi in ICU"ICN Victoria: Cornely on "Being a Fun-gi in ICU"
ICN Victoria: Cornely on "Being a Fun-gi in ICU"
 
Informe sobre la situación del uso de antimicrobianos en España
Informe sobre la situación del uso de antimicrobianos en EspañaInforme sobre la situación del uso de antimicrobianos en España
Informe sobre la situación del uso de antimicrobianos en España
 
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for PigsDr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
 
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for PigsDr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
Dr. Jorge Garrido - Cost Effective Influenza Sampling Strategies for Pigs
 
WYETH 2009 ICAAC POSTER 1
WYETH 2009 ICAAC POSTER 1WYETH 2009 ICAAC POSTER 1
WYETH 2009 ICAAC POSTER 1
 
Résistance de P. falciparum au Nigeria
Résistance de P. falciparum au NigeriaRésistance de P. falciparum au Nigeria
Résistance de P. falciparum au Nigeria
 
9 stephen mulligan
9 stephen mulligan9 stephen mulligan
9 stephen mulligan
 
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
1090716-非小細胞肺癌於精準醫療治療下的診斷與治療
 
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
OS20 - Development of Solid-phase Competition ELISA for detection of type-A F...
 
5-Clinical_evaluation_data-_SARS-CoV-2_-Lin_Chuang_Bao_Gao_.pdf
5-Clinical_evaluation_data-_SARS-CoV-2_-Lin_Chuang_Bao_Gao_.pdf5-Clinical_evaluation_data-_SARS-CoV-2_-Lin_Chuang_Bao_Gao_.pdf
5-Clinical_evaluation_data-_SARS-CoV-2_-Lin_Chuang_Bao_Gao_.pdf
 
study of egfr protein expression by Immunohistochemistry and mutation check b...
study of egfr protein expression by Immunohistochemistry and mutation check b...study of egfr protein expression by Immunohistochemistry and mutation check b...
study of egfr protein expression by Immunohistochemistry and mutation check b...
 
Molecular epidemiology of carbapenemase-producing Klebsiella pneumoniae in Hu...
Molecular epidemiology of carbapenemase-producing Klebsiella pneumoniae in Hu...Molecular epidemiology of carbapenemase-producing Klebsiella pneumoniae in Hu...
Molecular epidemiology of carbapenemase-producing Klebsiella pneumoniae in Hu...
 
Study on Sensitivity Pattern of Micro-Organisms in Respiratory Tract Infectio...
Study on Sensitivity Pattern of Micro-Organisms in Respiratory Tract Infectio...Study on Sensitivity Pattern of Micro-Organisms in Respiratory Tract Infectio...
Study on Sensitivity Pattern of Micro-Organisms in Respiratory Tract Infectio...
 
J World's Poult Res 5(2) 21-28, 2015
J World's Poult Res 5(2) 21-28, 2015J World's Poult Res 5(2) 21-28, 2015
J World's Poult Res 5(2) 21-28, 2015
 

Mais de Zelekewoldeyohannes (20)

Cerebral edema.pptx
Cerebral edema.pptxCerebral edema.pptx
Cerebral edema.pptx
 
Additional notes on MG.pptx
Additional notes on MG.pptxAdditional notes on MG.pptx
Additional notes on MG.pptx
 
Hypoglycemic Encephalopathy.pptx
Hypoglycemic Encephalopathy.pptxHypoglycemic Encephalopathy.pptx
Hypoglycemic Encephalopathy.pptx
 
Dizziness.pptx
Dizziness.pptxDizziness.pptx
Dizziness.pptx
 
Chorea.pptx
Chorea.pptxChorea.pptx
Chorea.pptx
 
Approach to Neuromuscular Disorders.pptx
Approach to Neuromuscular Disorders.pptxApproach to Neuromuscular Disorders.pptx
Approach to Neuromuscular Disorders.pptx
 
Cranial Nerve Seven.pptx
Cranial Nerve Seven.pptxCranial Nerve Seven.pptx
Cranial Nerve Seven.pptx
 
Immune.pptx
Immune.pptxImmune.pptx
Immune.pptx
 
ATAXIA.pptx
ATAXIA.pptxATAXIA.pptx
ATAXIA.pptx
 
DizzinessanddistconcsJune2013.pptx
DizzinessanddistconcsJune2013.pptxDizzinessanddistconcsJune2013.pptx
DizzinessanddistconcsJune2013.pptx
 
Brain stem New.ppsx
Brain stem New.ppsxBrain stem New.ppsx
Brain stem New.ppsx
 
Paraplegia.pptx
Paraplegia.pptxParaplegia.pptx
Paraplegia.pptx
 
Extrapyramidal Disorders.pptx
Extrapyramidal Disorders.pptxExtrapyramidal Disorders.pptx
Extrapyramidal Disorders.pptx
 
dvt-good.ppt
dvt-good.pptdvt-good.ppt
dvt-good.ppt
 
Joint session discussion.pptx
Joint session discussion.pptxJoint session discussion.pptx
Joint session discussion.pptx
 
Hyperkinetic movement disorder.pptx
Hyperkinetic movement disorder.pptxHyperkinetic movement disorder.pptx
Hyperkinetic movement disorder.pptx
 
Diseases of the eye.pdf
Diseases of the eye.pdfDiseases of the eye.pdf
Diseases of the eye.pdf
 
Vitamin A deficinecy.pptx
Vitamin A deficinecy.pptxVitamin A deficinecy.pptx
Vitamin A deficinecy.pptx
 
Trachoma.pptx
Trachoma.pptxTrachoma.pptx
Trachoma.pptx
 
Retinoblastoma.pptx
Retinoblastoma.pptxRetinoblastoma.pptx
Retinoblastoma.pptx
 

Último

Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptxVS Mahajan Coaching Centre
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfciinovamais
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfsanyamsingh5019
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesFatimaKhan178732
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphThiyagu K
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13Steve Thomason
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxSayali Powar
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 

Último (20)

Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions  for the students and aspirants of Chemistry12th.pptxOrganic Name Reactions  for the students and aspirants of Chemistry12th.pptx
Organic Name Reactions for the students and aspirants of Chemistry12th.pptx
 
Activity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdfActivity 01 - Artificial Culture (1).pdf
Activity 01 - Artificial Culture (1).pdf
 
Sanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdfSanyam Choudhary Chemistry practical.pdf
Sanyam Choudhary Chemistry practical.pdf
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
Separation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and ActinidesSeparation of Lanthanides/ Lanthanides and Actinides
Separation of Lanthanides/ Lanthanides and Actinides
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13The Most Excellent Way | 1 Corinthians 13
The Most Excellent Way | 1 Corinthians 13
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptxPOINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
POINT- BIOCHEMISTRY SEM 2 ENZYMES UNIT 5.pptx
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 

2014 E. C UoGCSHL Antibiogram pdf.pdf

  • 1. University of Gondar College of Medicine and Heath Sciences and University of Gondar comprehensive specialized hospital Medical Microbiology Laboratory Annual antibiogram from July 2013 – June 2014 E. C. Specimens are mostly blood and urine.
  • 2. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Gram positive and Gram negative bacterial isolates (515). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility 0 50 100 150 200 250 300 350 400 Penici llin G Ampic illin Piper acillin Oxacil lin Piper acillin /Tazo bacta m Cefur oxime Ceftaz idime Ceftri axone Cefot axime Cefoxi tin Mero pene m Amika cin Genta micin Tobra mycin Ciprof loxaci n Trime thopri m/Sul famet hoxaz ole Nitrof urant oin Vanco mycin Chlor amph enicol Number 146 46 39 140 161 43 162 255 45 140 259 119 360 61 262 203 58 37 98 %S 9.6 6.5 30.8 42.1 57.8 11.7 23.5 22.7 6.7 42.1 81.9 80.7 47.2 44.3 40.9 31 82.8 59.5 54 Number & % susceptibility Name of antimicrobial Number %S
  • 3. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Gram negative bacterial isolates (329). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility 0 100 200 300 Ampicil lin Piperac illin Piperac illin/Taz obacta m Cefurox ime Ceftazi dime Ceftriax one Cefotax ime Merop enem Amikaci n Genta micin Tobram ycin Ciproflo xacin Trimeth oprim/ Sulfam ethoxaz ole Nitrofu rantoin Chlora mpheni col Number 43 37 160 41 157 219 43 256 117 228 58 246 178 56 85 %S 4.7 32.4 57.5 9.8 24.2 20.1 4.7 82 81.2 43.4 41.4 39 25.8 82.1 52.9 Number & % susceptibility Name of antimicrobial Number %S
  • 4. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH NICU for all Gram negative bacterial isolates (132). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility  NICU = Neonatal intensive care unit 0 20 40 60 80 100 120 Piperacillin /Tazobacta m Ceftazidim e Ceftriaxone Meropene m Amikacin Gentamicin Ciprofloxaci n Trimethopr im/Sulfame thoxazole Chloramph enicol Number 71 60 85 103 41 97 99 71 38 %S 64.8 25 24.7 83.5 75.6 36 45.5 35.2 39.5 Number & % Susceptibility Name of antimicrobial Number %S
  • 5. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH NICU for all E. coli bacterial isolates (89). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility  NICU = Neonatal intensive care unit 0 10 20 30 40 50 60 70 80 90 100 Piperacillin/ Tazobacta m Ceftazidime Ceftriaxone Meropene m Amikacin Gentamicin Ciprofloxaci n Trimethopri m/Sulfamet hoxazole Nitrofurant oin Number 39 41 62 75 34 65 64 50 35 %S 61.5 22 22.6 97.3 85.3 60 25 20 85.7 Number & % susceptibility Name of antimicrobial Number %S
  • 6. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all K. pneumoniae isolates (127). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility 0 20 40 60 80 100 120 Piperacillin/ Tazobactam Ceftazidime Ceftriaxone Meropene m Amikacin Gentamicin Ciprofloxaci n Trimethopri m/Sulfamet hoxazole Chloramph enicol Number 62 57 83 101 38 84 88 72 40 %S 51.6 22.8 14.5 78.2 84.2 23.8 38.6 26.4 50 Number & % susceptibility Name of antimicrobial Number %S
  • 7. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Klebsella spps isolates (144). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility 0 20 40 60 80 100 120 Piperacilli n/Tazobac tam Ceftazidim e Ceftriaxon e Meropene m Amikacin Gentamici n Tobramyci n Ciprofloxa cin Trimethop rim/Sulfa methoxaz ole Chloramp henicol Number 69 66 95 115 46 96 30 101 82 48 %S 50.7 24.2 14.7 79.1 82.6 27.1 36.7 38.6 25.6 52.1 Number & % susceptibility name of antimicrobial Number %S
  • 8. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH NICU for all Klebsella spps isolates (86). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility  NICU = Neonatal intensive care unit 0 10 20 30 40 50 60 70 80 90 Piperacillin/T azobactam Ceftazidime Ceftriaxone Meropenem Gentamicin Ciprofloxacin Trimethopri m/Sulfameth oxazole Chloramphen icol Number 45 32 50 70 59 56 47 32 %S 60 15.6 14 82.9 20.3 37.5 29.8 40.6 Number & % susceptibility Name of antimicrobia Number %S
  • 9. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Non fermenter bacterial isolates including Acinetobacter spps and Pseudomonas spps (67). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility 0 10 20 30 40 50 60 70 Piperacillin/Tazob actam Ceftazidime Ceftriaxone Meropenem Gentamicin Ciprofloxacin Number 40 32 42 49 49 57 %S 57.5 31.3 26.2 65.3 53.1 56.1 Number & % susceptibility Name of antimicrobial Number %S
  • 10. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all Gram positive bacterial isolates (180). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility 0 20 40 60 80 100 120 140 160 Penicillin G Oxacillin Ceftriaxone Cefoxitin Gentamicin Vancomycin Number 146 140 30 140 127 37 %S 9.6 42.1 43.3 42.1 54.3 59.5 Number & % susceptibility Name of antimicrobial Number %S
  • 11. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH for all S. aureus isolates (141). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility 0 20 40 60 80 100 120 140 Penicillin G Oxacillin Cefoxitin Gentamicin Number 132 137 137 125 %S 6.1 43.1 43.1 54.4 Number & % susceptibility Name of antimicrobial Number %S
  • 12. Annual antibiogram (July 2013 – June 2014 E.C) in UoGCSH NICU ward for all S. aureus isolates (55). Key:  Number = Number of each antimicrobial repeatedly tested  %S = %susceptibility  NICU = Neonatal intensive care unit 0 10 20 30 40 50 60 Penicillin G Oxacillin Cefoxitin Gentamicin Number 55 54 54 53 %S 3.6 40.7 40.7 43.4 Number & % susceptibility Name of antimicrobial Number %S